Skip to main content
. Author manuscript; available in PMC: 2015 Dec 17.
Published in final edited form as: Cochrane Database Syst Rev. 2014 Dec 17;12:10.1002/14651858.CD008940.pub2. doi: 10.1002/14651858.CD008940.pub2

SUMMARY OF FINDINGS FOR THE MAIN COMPARISON [Explanation]

Active medication compared with placebo
 
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)		 No of participants
(studies)		 Quality of the evidence
(GRADE)		 Comments
Assumed risk Corresponding risk
Control Active Medication
Number abstinent at end
of treatment - mixed ac
tion antidepressants 		Study population
RR 0.82
(0.12 to 5.41)		 179
(2 studies)		 ⊕○○○
very low1,2
250 per 1000 205 per 1000
(30 to 1000)
Moderate
233 per 1000 191 per 1000
(28 to 1000)
*

The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

1

Significant heterogeneity between studies

2

Studies small (<300 participants in total)